Dorairajan Gowri, Ravi Saranya, Chinnakili Palanivel
Department of Obstetrics and Gynaecology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Department of Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
J Pregnancy. 2024 Dec 19;2024:8835464. doi: 10.1155/jp/8835464. eCollection 2024.
Preinduction cervical ripening in previous caesarean pregnancy is limited to intracervical Foley catheter. This study is aimed at finding the vaginal birth rates, improvement of Bishop score, and safety of osmotic dilator (Dilapan-S) among women with previous caesarean pregnancy. We conducted this single-group clinical study after the approval of the institute ethics committee, clinical trial registration, and obtaining informed consent. We recruited women above 18 years with a prior caesarean section at term and a Bishop score of less than 6 by systematic random sampling prospectively. The first or second author inserted two to a maximum of five osmotic dilators (Dilapan-S) in the cervical canal. After 24 h, we removed Dilapan and induced labour with a low-dose oxytocin regimen up to a maximum dose of 24 mIU/min. We assessed the improvement of the Bishop score and vaginal birth rates for efficacy and safety concerns like bleeding, fragmentation, displacement, infections, and scar dehiscence. Eighty-two women completed the study. The Bishop score significantly improved from a mean of 2.6 before to 5.3 after Dilapan. Three opted for a caesarean section after Dilapan removal and refused oxytocin infusion. Seventy-nine women completed the trial of labour. Forty-one (52%) achieved active labour (52%). Twenty-seven delivered vaginally, and 52 required emergency caesarean section (34% vaginal birth rate; 18 spontaneous, nine instrumental, four with forceps, and five with vacuum). None had entrapment, fragmentation, or upward displacement of Dilapan. Two women had scar dehiscence, and one had a traumatic postpartum haemorrhage. There was no maternal or perinatal mortality. We conclude that the hygroscopic dilator Dilapan effectively ripens the cervix before labour induction in women with a previous caesarean scar. They are safe, but more extensive studies are needed to evaluate scar-related complications during labour. : Clinical Trial Registry of India: CTRI/2019/03/017927.
既往剖宫产史孕妇引产术前的宫颈成熟方法仅限于宫颈内放置福勒氏导尿管。本研究旨在探讨既往有剖宫产史的孕妇使用渗透扩张器(Dilapan-S)后的阴道分娩率、Bishop评分改善情况及安全性。本单组临床研究经机构伦理委员会批准、临床试验注册并获得知情同意后开展。我们通过系统随机抽样前瞻性招募了年龄在18岁以上、足月前有剖宫产史且Bishop评分小于6分的女性。第一或第二作者在宫颈管内放置2至最多5个渗透扩张器(Dilapan-S)。24小时后,取出Dilapan并采用低剂量缩宫素方案引产,最大剂量为24 mIU/分钟。我们评估了Bishop评分的改善情况和阴道分娩率,以及出血、破碎、移位、感染和瘢痕裂开等疗效和安全性问题。82名女性完成了研究。Dilapan放置后,Bishop评分从术前平均2.6分显著提高至5.3分。3名女性在取出Dilapan后选择剖宫产并拒绝缩宫素输注。79名女性完成了引产试验。41名(52%)进入活跃期分娩(52%)。27名经阴道分娩,52名需要急诊剖宫产(阴道分娩率34%;18名自然分娩,9名器械助产,4名产钳助产,5名真空吸引助产)。无一例出现Dilapan嵌顿、破碎或上移。2名女性出现瘢痕裂开,1名出现创伤性产后出血。无孕产妇或围产儿死亡。我们得出结论,吸水性扩张器Dilapan在既往有剖宫产瘢痕的女性引产术前能有效促进宫颈成熟。它们是安全的,但需要更广泛的研究来评估分娩期间与瘢痕相关的并发症。:印度临床试验注册中心:CTRI/2019/03/017927